Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
FDA Delays Approvals For Gilead Sciences
by Ann M. Thayer
May 6, 2013
| A version of this story appeared in
Volume 91, Issue 18
FDA has told Gilead Sciences that it won’t approve elvitegravir and cobicistat, two HIV drugs the company hopes to launch as individual products. Both drugs are components of Gilead’s Stribild, a single-tablet, four-drug combination that patients take once daily. Although FDA approved Stribild in August 2012 and the company can still sell it, the agency found deficiencies in quality-testing procedures and methods during recent inspections of manufacturing processes for elvitegravir and cobicistat. Gilead says it is working with FDA to address the problems.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter